The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity' or 'the Company') is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.

Dr Stamler joined the Company in June 2017 as Chief Medical Officer and Senior Vice President Clinical Development. Mr Geoffrey Kempler, who founded the company in November 1997, will step down from the role of CEO and continue as Non-Executive Chairman.

Mr Kempler will be engaged in a consulting capacity in addition to his Non-Executive Chairman role.

Dr Stamler has significant pharmaceutical development and commercialisation experience including three New Drug Application approvals with the US FDA for drugs in the neurological space. His succession aligns with the next phase of Alterity's commercial strategy and comes at a time when the company is preparing to advance its lead compound ATH434 to Phase 2 Clinical trials.

Mr Kempler said: 'It's been a great privilege to work towards improving the lives of millions of people suffering from neurodegenerative diseases. I have had the honour of working with teams of very dedicated scientists and clinicians over many years. I am delighted that David Stamler, who joined Alterity over 3 years ago, has agreed to succeed me and assume the role of CEO. David is enormously talented, and I look forward to continuing to work with him as we continue to advance our treatments for Parkinsonian diseases'.

Dr Stamler added: 'When I first joined Alterity I was impressed and excited at the novel technology that underpins our portfolio of potential treatments for neurodegenerative disease and since then have been pleased with the progress we've made. We are at an important juncture as we move into later stage clinical trials for our lead compound ATH434 and I look forward to now leading the business as CEO and advancing our commercialisation program.'

The revised contract for both Dr David Stamler and Mr Geoffrey Kempler has considered ASX Corporate Governance Principles and Recommendations as well as industry practice. The key terms of the contracts, in accordance with Listing Rule 3.16.4, are set out in the attachment to this announcement.

END

Authorization & Additional information
 This announcement was authorized by Mr Geoffrey Kempler, Chairman of Alterity Therapeutics Limited.

Attachments

  • Original document
  • Permalink

Disclaimer

Alterity Therapeutics Ltd. published this content on 07 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 January 2021 23:13:01 UTC